Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2670

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2670
---
refusal to file” letter or a request for additional information;

122

    ●
    adverse
    results or delays in our clinical trials;

    ●
    our
    decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;

    ●
    adverse
    regulatory decisions, including failure to receive regulatory approval of any product candidate;

    ●
    changes
    in laws or regulations applicable to any product candidate, including but not limited to clinical trial requirements for approvals;

    ●
    adverse
    developments concerning our manufacturers;

    ●
    our
    inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;

    ●
    our
    inability to establish collaborations, if needed;

    ●
    our
    failure to commercialize our product candidates, if approved;

    ●
    additions
    or departures of key scientific or management personnel;

    ●
    unanticipated
    serious safety concerns related to the use any of our product candidates;

    ●
    introduction
    of new products or services offered by us or our competitors;

    ●
    announcements
    of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;

    ●
    our
    ability to effectively manage our growth;

    ●
    actual
    or anticipated variations in quarterly operating results;

    ●
    our
    cash position;

    ●
    our
    failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;

    ●
    publication
    of research reports about us or our industry, or product candidates in particular, or positive or negative recommendations or withdrawal
    of research coverage by securities analysts;

    ●
    changes
    in the market valuations of similar companies;

    ●
    changes
    in the structure of the healthcare payment systems;

    ●
    overall
    performance of the equity markets;

    ●
    sales
    of our common stock and public warrants by us or our stockholders in the future;

    ●
    trading
    volume of our common stock and public warrants;

    ●
    changes
    in accounting practices;

    ●
    ineffectiveness
    of our internal controls;

    ●
    disputes
    or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection
    for our technologies;

123

    ●